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Abstract  
Nanoporous bioceramic recently has gained attention as a drug storage and release host in the therapeutic application. Mesoporous 
carbonated hydroxyapatite (MCHA) is a nanoporous bioceramic with pore sized ranged between 2-50 nm. In order to use in drug 
delivery application, this material should demonstrate acceptable cytotoxic activity and osteoinductive response. Therefore, this 
study aimed to evaluate the effect of mesoporous carbonated hydroxyapatite on viability and alkaline phosphatase (ALP) activity 
of MC3T3-E1 osteoblasts cell line. These parameters represent cytotoxicity level and osteinductivity capability of the materials. 
MC3T3-E1 cells were cultured in 25 mg/ml extraction of mesoporous carbonated hydroxyapatite (meso-CHA) and non-porous 
CHA (np-CHA) for up to 7 days for viability and 14 days for ALP test. Results indicate that meso-CHA shows better cytotoxicity 
properties compare to np-CHA. Intracellular ALP of cells treated with meso-CHA was higher than np-CHA. 
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1. Introduction 
Porous materials with ordered structure have become an interesting  and popular topic for research in adsorptions 
since the discovery of Mobil Composition of Matter No. 41 (MCM-41) in 19921. According to International Union of 
Physical and Applied Chemistry (IUPAC) classification, pores can be categorize as micropore (pore size < 2 nm), 
mesopore ( 2 < pore size < 50 nm) and macropore  ( pore size > 50 nm)2.  As these pore sizes fall within the nanoscale 
range, they can also be described as nanopores. Macroporous hydroxyapatite (HA) which have similar chemical 
composition to human bone and teeth have been utilized as a vehicle for the delivery of pharmaceuticals molecules 
such as ibuprofen3-6, alendronate7, zolendronate8, vancomycin9, norfloxacin10 and carvedilol11 to the treated area. 
Macroporous HA exhibited the ‘burst’ release (the sudden  release of a drug in large amounts at the initial stage of the 
delivery period)  profile during drug delivery process12. This behaviour is considered as a major drawback for its 
application in drug delivery. It can be attributed to the fact that drug molecules tend to concentrate on the external 
surface of dense materials rather than attaching to the internal pores13. Consequently, dense and macroporous HA with 
lower porosity and larger external surface in relative to internal surface area increases the possibility for 'burst' release 
to occur and thus, less suitable to be used as drug carrier for controlled release. It would be relatively easier for drug 
molecules to be adsorbed by material with larger surface area and higher adsorption strength. Mesoporous materials 
have smaller pore size, larger surface area and higher adsorption strength can load more drugs and release in a 
controllable manner and thus is a much better candidate as a vehicle for drug release.  
Carbonated hydroxyapatite is a nonstoichiometric version of HA14. The substitution of carbonate in the 
crystal structure is known to weaken the apatite structure and makes it more soluble15. Thus, carbonated 
hydroxyapatite (CHA), which is chemically more similar to human bone constituents, has therefore shown to 
demonstrated better biocompatibility, bioactivity, and resorbability14, 16 compared to HA. For this reason, a better 
profile of drug adsorption and release is expected from mesoporous CHA. Biocompatibility is the main concerned for 
biomaterials; therefore all new developed biomaterials must fulfill specific criteria laid out by the government 
authorities and international agencies, before receiving approval for clinical application. In practice, standard cell-
based toxicity assays are performed in-vitro to evaluate cytotoxic level of the biomaterials. It is important to consider 
the possible impact of the materials on the process linked to cell proliferation and differentiation. Hence it would be 
of interest to evaluate the cytotoxicity properties of the mesoporous carbonated hydroxyapatite materials and the effect 
of this material on the cell differentiations. The aim of this study is to determine the level of toxicity of the in-house 
synthesise mesoporous CHA and to confirm the effect of mesopore within the CHA nanopowders on cell 
differentiation compared to non-porous CHA. 
2. Methodology 
2.1 Sample Preparation 
Mesoporous carbonated hydroxyapatite (meso-CHA) nanoparticles was synthesise using calcium nitrate 
tetrahydrate (Ca(NO3)2.4H2O), and diammonium hydrogen phosphate ((NH4)2.HPO4) as calcium and phosphate 
precursor, respectively. Pluronics® P123 (BASF, USA) was used as non-ionic surfactant to create pore within 
nanoparticles. As described in our previous paper17, 18, initially surfactant-calcium ion containing solution was 
prepared by dissolving 1 g of  P123 in 100 mL of deionised water (DI water) followed by the addition of  9.45 g of 
Ca(NO3)2.4H2O. The solution was then stirred for 30 minutes. The source of phosphate ion was prepared by dissolving 
3.17 g of (NH4)2.HPO4 in 60 ml of DI water. Next, the phosphate ion containing solution was mixed with 3.795 g of 
ammonium hydrogen carbonate (NH4HCO3) as a carbonate ion source. Subsequently, the prior prepared phosphate-
carbonate mixture was dripped slowly into the surfactant-calcium containing solution under continuous stirring, 
producing the milky solution. The alkanity of the milky solution was maintained at pH 11 throughout the mixing 
process. The milky solutions then poured into a Teflon® bottle and aged at 120°C in an oven for 24 hours. Next, the 
solution was cooled down and centrifuged at 3000 rpm for 20 minutes to obtain the white precipitate. The excess 
surfactant was removed from the precipitate by washing and centrifuging for five times with DI water. The white 
precipitate then dried in an oven at 100°C for 24 hours. The dried precipitate was then ground into fine powders by 
using mortar and pestle and further calcined in a furnace at 550 °C for 6 hours.  In this study, the biocompatibility of 
synthesise meso-CHA was compared to nonporous carbonated hydroxyapatite (np-CHA). Sample np-CHA was 
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prepared using the similar method that mentions previously, but without the addition of P123.  
2.2 Sample Characterization 
The phase and crystallographic structures of synthesised samples were identified by X-ray diffraction (XRD) 
(Bruker AXS D8) diffractometer using CuKα radiation (λ = 0.15406) over the range of 10° ≤ 2θ ≤ 90. The Fourier 
Transform Infrared (FTIR) analysis was performed using Perkin Elmer Spectrum One spectrophotometer in the range 
of wave numbers of 4000-400 cm-1 for the identification of functional group that represent carbonated hydroxyapatite. 
Morphological and nanoparticle shape of the samples was investigated by using Zeiss SUPRA 35VP field emission 
scanning electron microscopy (FESEM). High-resolution transmission electron microscope (HRTEM) model 
Technai™, G2 F20 S-Twin was used to verify pore formation within the sample. Nitrogen adsorption-desorption 
analysis was conducted using Quantachrome Autosorb® IQ at 77 K to evaluate the surface area and pore characteristic 
of the samples. The samples were pre-treated by degassing at 573.15 K for 8 hours. Brunauer-Emmett-Teller (BET) 
equation was used to calculate the specific surface area of the samples. The pore size distribution (PSD) of the samples 
was calculated from the desorption data of the isotherms using density functional theory (DFT) model. 
2.3 Preparation of nanoparticle extract 
Firstly, all of the sample powders were put under the ultra violet light for 30 minutes for sterilization. Then, 0.25 
g of each nanopowders were immersed in 10 ml alpha minimum essential medium (Alpha-MEM, Gibco, USA) in 
incubators for 24 hours at 37°C to obtained the extract with the concentration of 25 mg/ml. Subsequently, the extract 
was separated from the powders by centrifuging at 3000 rpm for 10 minutes. 
2.4 Cell culture studies 
Osteoblast-like cells MC3T3-E1 (Riken, Japan) were used in this study. The Alpha-MEM (Gibco, USA) 
containing 10% fetal bovine serum (FBS) and 1% penicilin-streptomycin (Gibco, USA) was used as the culture 
medium.  The cells were culture in 75 cm2 flasks (Nunc, Denmark) inside the incubator at 37°C with 5% CO2 and 
95% relative humidity. Cells were cultured until confluenced by changing the culture medium every three days of 
incubation.   
 
2.4.1 Cytotoxicity study  
 
In vitro cytotoxicity study was conducted using indirect method as per ISO 10993-5 19. Cells cultured in 75 cm2 
flasks were trypsinized using TrypLETM Express (Gibco, USA), suspended in a complete Alpha-MEM, and subculture 
in 96-well culture plates at a cell density of 5000 cells/well with 100 μl of culture medium. The medium was discarded 
from each well after 24 hours of incubation and 100 μl of 25 mg/ml extracts of the samples were added into the wells. 
Cells without addition of extracts of the materials served as a negative control. The cells were further incubated for 1, 
3, 5 and 7 days. The cytotoxicity of the samples was evaluated by assessing  the cell viability using CellTiter 96® 
AQueous One Solution Reagent (Promega, USA) which contain a novel  tetrazolium  compound (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS) and electron coupling 
reagent (phenazine ethosulfate, PES). At the end of each incubation period, the assay was added with 20 μl of the 
reagent and re-incubated in 5% CO2 and 95% relative humidity at 37°C for 4 hours. After 4 hours of incubation, the 
yellow colour of the reagent changed to brown with different level of concentration. Then, an enzyme-linked 
immunosorbent assay (ELISA) reader (Sunrise, Tecan, Austria) was used to measure the absorbance of the assay at 
492 nm. The cell viability was measured as a ratio of the optical density of the extract medium of treated cell to the 
optical density of the medium of non-treated cells (control group) using the following formula:  
 
Cell viability % = [Absorbance of medium of treated cells/Absorbance of medium controls cells] x 100%.            (1) 
 
If viability is less than 70%, the test sample has a cytotoxic potential. Thus, the lower the cell viability value, the 
higher the cytotoxicity of the tested item. 
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2.5.2 Cell differentiation study by assessment of alkaline phosphatase (ALP) activity 
Effect of materials on cell differentiation was investigated using alkaline phosphatase (ALP) test.  Bone alkaline 
phosphatase (ALP) is a bone cell-specific marker that is expressed by the cells during the matrix maturation phase.  
The expression of ALP by the cells reflect that cell differentiate for bone formation and mineralization20. In this study, 
ALP activity was studied on 3rd, 7th and 14th day after the addition of meso-CHA and np-CHA in the MC3T3-E1 cells 
line. ALP activity was detected by the hydrolysis of p-nitrophenyl phosphate (pNPP) to p-nitrophenol using Alkaline 
Phosphatase Activity Colometric Assay Kit (Biovision, USA) according to manufacturer's protocols. Cells were 
cultured in triplicate at 5000 cells per well in a 24-well plate (Nunc, Denmark) with 500 μL of culture medium until 
they reached 80% confluence. Then, medium was discarded from each well and cells were treated with 500 μL of 25 
mg/ml of meso-CHA and np-CHA extract. Cells without addition of extracts of the materials served as a negative 
control. Culture extract medium was changed every three days of incubation. Culture media was discarded from each 
well at the end of each incubation period and subsequently washed twice with the phosphate buffer saline (PBS). The 
cells were then lysed with Assay Buffer solutions. The insoluble material was separated from the lysed cells by 
centrifuging at 13,000 rpm for 3 minutes. About, 80 μl of supernatant obtained from the centrifugation of each sample 
was pipetted into 96-well plate and added with 50 μl of the pNPP solution, mix well and incubated at 25 °C for 60 
minutes. Finally, stop solution (20 μl) was added to stop the ALP reaction and the absorbance was read at 405 nm 
using ELISA reader (Sunrise, Tecan, Austria). ALP activity of the cells in each extract was calculated using the 
following equation:  
 
ALP activity (U/ml) = A/V/T                    (2) 
 
where A is the amount of pNP generated by the samples (in μmol), V is the volume of the sample added in the assay 
well (in ml), and T is the reaction time (in minutes). 
2.5.3 Statistical analysis 
The SPSS software version 16.0 was used for the one-way analysis of variance of the data followed by a 
multiple comparison Tukey test. Statistical significance was defined as P value < 0.05. 
3. Results and discussions 
3.1 Characterization of the samples 
The X-ray diffraction patterns of the synthesised samples are shown in Fig. 1 (a). Sample meso-CHA  and np-
CHA show the pure phase of CHA with the substitution of CO3− ions at the phosphate site, which corresponds to the 
standard characteristic peaks of carbonate apatite with lattice constant of  a = 9.3450 Å and c = 6.920 Å (space group 
hexagonal P63/m, PDF Number 98-010-1164). The main characteristic peaks of CHA at 2θ = 25.8, 31.8, 32.1° and 
33° 21-25 which can be indexed at (002), (121), (112) and (300), were clearly observed in the XRD pattern of sample 
np-CHA but the peak correspond to (112) were absence in the XRD pattern of meso-CHA due to broadening of the 
pattern. The main difference between the samples is the level of crystallinity of the materials. The broad diffractions 
peak of meso-CHA indicates that mesoporous carbonated hydroxyapatite synthesised with the substitution of 
surfactant was less crystalline than those synthesised without surfactant (np-CHA). Sample synthesise with P123 has 
the lower fraction of crystallinity (Xc = 0.5196) than non-porous sample (Xc = 0.8403). The crystallinity was taken 
into consideration in this study because low crystallinity fraction would confer a higher bioresorbability of CHAp26. 
Highly resorbable materials are favourable in drug delivery application in order to obtain a controlled release of drug 
delivery from the carrier particles. 
Fig. 2 exhibits the FTIR spectra of meso-CHA and np-CHA with the bands being labelled accordingly for different 
functional groups. The bands present at 3568 cm−1 of FTIR spectra are designated for OH−1 27, 28. The absorption peaks 
at 1050 and 962 attributed to the stretching vibration (v3) of the phosphate (PO43−) groups, and the absorption peaks 
at 603 cm−1 and 567 cm−1 are corresponding to bending vibration (v4) of the phosphate (PO43−) groups 7, 27. The broad 
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band at around 3435 cm−1 is corresponding to OH group29. The absorption band around 1092 is due to HPO42− ions, 
indicating that both material is calcium-deficient apatite30. The characteristic bands of B-type CO3−2 substitution  are 
observed at  1472, 1416, and 872 cm−1 31. This finding verified that meso-CHA and np-CHA are B-type carbonated 
hydroxyapatite, where by the carbonate ions were substituted at the phosphate ions atomic site in the hydroxyapatite 
lattice32, 33. Therefore, the synthesised carbonate apatite can be expressed as Ca10-x/2[(PO4)6-xCO3)x][(OH2-2y(CO3)y], 
where x and y are numbers of CO32- ions substituting for  PO43- and OH, respectively 34.  
 
 
     
  Fig.1. XRD diffraction patterns of meso-CHA and np-CHA.                     Fig. 2. FTIR spectra of meso-CHA and np-CHA samples. 
 
 
 
 
 
Fig. 3. The (a) FESEM and (b) HRTEM image of nanoparticles of meso-CHA. 
 
 
FESEM and HRTEM images of sample meso-CHA are shown in Fig. 3.  Fig. 3 (a) shows that meso-CHA 
consists of agglomerated spherical-shaped nanoparticles. However, due to highly agglomerated nanoparticles, the 
spherical-shaped of meso-CHA was not clearly observed by the HRTEM in Fig. 3 (b).  Van der Waals force attraction 
between the nanoparticles most probably leads to this formation of fine agglomerates. Pores were randomly distributed 
and not in precisely ordered of alignment.  
 
The mesoporous structure of meso-CHA, is confirmed by the nitrogen adsorption-desorption isotherms and the 
corresponding DFT pore size distribution curve (Fig. 4 (a)). The meso-CHA exhibit the Type IV isotherms with H1 
hysteresis loop. The H1 hysteresis loop is often associated with porous materials that consist of agglomerates or 
compacts of approximately uniform spheres in a fairly regular array35. The isotherms curves of np-CHA is identified 
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as Type III isotherms with H3 hysteresis loop which indicates that the sample consists of aggregates of plate-like 
particles, giving rice to slit-shaped pores35. Since the slit-shaped pore due to aggregation of particles, the surface area 
given is rather low, 4 m2g-1. The inset graphs in Fig. 4 shows the corresponding DFT pore size distribution curve. The 
pore size for meso-CHA is mainly distributed at 28.4 nm, meanwhile for np-CHA, the pore size is mainly distributed 
at 11.7 nm. Sample meso-CHA demonstrated the highest BET surface area of 77.5 m2g-1 compared to np-CHA. 
 
 
Fig. 4. N2 adsorption-desorption isotherms of samples (a) meso-CHA and (b) np-CHA  The inset graph shows the corresponding DFT pore size 
distribution. 
 
3.2 Cytotoxicity study  
The cytotoxic nature of the samples was assessed with MTS assay after cultured for 1, 3, 5 and 7 days. The MC3T3-
E1 cells were cultured in 25 mg/ml of meso-CHA and np-CHA extract.  The biocompatible nature of meso-CHA was 
clearly revealed by the viability study using MC3T3-E1 cell line. Cells exhibited more than 70% viability at each 
incubation period (Fig.5), indicating that meso-CHA and np-CHA are non-toxic materials. The time-dependent result 
showed that cell viability of meso-CHA is significantly higher than np-CHA on day 1 and day 7 of incubation period 
(p<0.05).  No significant difference on cell viability of the meso-CHA as compared to the control assay. These results 
confirmed that no toxic effect existed to deter normal cellular growth and proliferation in meso-CHA extracts, 
however, meso-CHA does not enhance the cells proliferation. 
 
 
Fig. 5. The cell viability percentage of the MC3T3-E1 exposed to the 25 mg/ml extract of meso-CHA, np-CHA and without extracts (control). 
3.3 Cell differentiation study by assessement  of ALP activity 
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As shown in Fig. 6, the ALP activity increased as the incubation time progressed. Mesoporous CHA and non-
mesoporous CHA samples shown to induce cell differentiation which conform to the usual pattern of ALP expression 
by bone-like cells20. The production of ALP was higher in the cells cultured in meso-CHA extract than in np-CHA 
extract, at all designed incubation periods, which is good for osteogenic development, due to the important role of 
ALP in cell differentiation and mineralization.  The ability of meso-CHA to increase ALP activity of the cells can be 
attributed to the calcium and phosphate ion rich environment that resulted from meso-CHA dissociation. It was found 
that these ions increased ALP activity of osteoblast36-38. Sample meso-CHA which has low crystallinity fraction is 
more resorbable than np-CHA, thus more calcium and phosphate ions were released from meso-CHA than np-CHA.  
 
Fig. 6. ALP activity on 3rd, 7th and 14th day of incubation. 
4. Conclusion 
This study demonstrated that mesoporous carbonated hydroxyapatite produce was non toxic and supported cell 
proliferation when compared to control assay.  After 7 days of culture, cell viability in meso-CHA is higher than np-
CHA. Sample meso-CHA also exhibited excellent osteinductive properties compared to np-CHA. This result indicates 
that mesoporous CHA is suitable to be used as a long term drug carrier since it does not induce cytotoxicity in the 
extended incubation period and more over did not deter normal cell proliferation and differentiation.  
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